Rhone-Poulenc Rorer Expands In Singapore
Franco-American pharmaceutical company Rhone-Poulenc Rorer is investing$50 million in the construction of a new chemical manufacturing plant in Singapore. The plant will be used for the production of enoxaparin sodium, which is the active ingredient for R-PR's low-molecular weight heparin Lovenox/Clexane injection.
The expansion will also include the construction of new laboratories, and the entire project will lead to the creation of 40 new jobs at the site. Construction of the new plant will get underway in September this year and manufacturing should start in 1999.
The site for the new plant was acquired by R-PR in October 1995 as a result of its acquisition of the UK company Fisons. Since 1993, the site has been used for the manufacture of the antiasthmatic agent Tilade (nedocromil sodium), and solutions for allergic conjunctivitis and allergic rhinitis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze